Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för John Maraganore. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att John Maraganore har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:AGIO / Agios Pharmaceuticals, Inc. | Director | 28 528 |
US:PROK / ProKidney Corp. | Director | 0 |
US:KYMR / Kymera Therapeutics, Inc. | Director | 24 000 |
US:ALNY / Alnylam Pharmaceuticals, Inc. | Chief Executive Officer, Director | 227 663 |
US:BEAM / Beam Therapeutics Inc. | Director | 13 133 |
US:BLUE / bluebird bio, Inc. | Director | 0 |
US:RGLS / Regulus Therapeutics Inc. | Director, 10% Owner | 0 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av John Maraganore. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderköp AGIO / Agios Pharmaceuticals, Inc. - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i AGIO / Agios Pharmaceuticals, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i AGIO / Agios Pharmaceuticals, Inc.. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderköp BEAM / Beam Therapeutics Inc. - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i AGIO / Agios Pharmaceuticals, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till max |
Pris vid max |
Max vinst ($) |
Maximal avkastning (%) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i AGIO / Agios Pharmaceuticals, Inc.. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till min |
Pris vid min |
Maximal förlust undvikits ($) |
Maximal förlust undvikits ($) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderköp KYMR / Kymera Therapeutics, Inc. - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i AGIO / Agios Pharmaceuticals, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till max |
Pris vid max |
Max vinst ($) |
Maximal avkastning (%) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i AGIO / Agios Pharmaceuticals, Inc.. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till min |
Pris vid min |
Maximal förlust undvikits ($) |
Maximal förlust undvikits ($) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderköp PROK / ProKidney Corp. - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i AGIO / Agios Pharmaceuticals, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till max |
Pris vid max |
Max vinst ($) |
Maximal avkastning (%) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i AGIO / Agios Pharmaceuticals, Inc.. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till min |
Pris vid min |
Maximal förlust undvikits ($) |
Maximal förlust undvikits ($) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av John Maraganore som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-02-03 |
|
5 | AGIO |
AGIOS PHARMACEUTICALS, INC.
Common stock |
G - Gift | −1 500 | 28 528 | −5,00 | ||||
2022-07-13 | 3 | PROK |
PROKIDNEY CORP.
No securities owned. |
0 | ||||||||
2022-05-24 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS, INC.
Restricted stock unit |
M - Exercise | −1 585 | 0 | −100,00 | ||||
2022-05-24 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS, INC.
Common stock |
M - Exercise | 1 585 | 30 028 | 5,57 | ||||
2022-01-19 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 24 000 | 24 000 | |||||
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −319 | 227 663 | −0,14 | 186,02 | −59 340 | 42 349 871 | |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −2 | 227 982 | 0,00 | 190,50 | −381 | 43 430 571 | |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −6 315 | 227 984 | −2,70 | 189,13 | −1 194 356 | 43 118 614 | |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 14 167 | 234 299 | 6,44 | ||||
2021-12-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −839 | 51 661 | −1,60 | ||||
2021-12-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −1 036 | 73 964 | −1,38 | ||||
2021-12-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −1 124 | 63 876 | −1,73 | ||||
2021-12-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −2 368 | 22 632 | −9,47 | ||||
2021-12-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 2 368 | 220 132 | 1,09 | 42,22 | 99 977 | 9 293 973 | |
2021-12-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 839 | 217 764 | 0,39 | 119,13 | 99 950 | 25 942 225 | |
2021-12-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 1 124 | 216 925 | 0,52 | 88,95 | 99 980 | 19 295 479 | |
2021-12-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 1 036 | 215 801 | 0,48 | 96,45 | 99 922 | 20 814 006 | |
2021-11-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −33 978 | 0 | −100,00 | |||
2021-11-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −670 | 214 765 | −0,31 | 174,34 | −116 808 | 37 442 130 |
2021-11-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −683 | 215 435 | −0,32 | 173,25 | −118 330 | 37 324 114 |
2021-11-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −14 518 | 216 118 | −6,29 | 172,22 | −2 500 290 | 37 219 842 |
2021-11-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −7 742 | 230 636 | −3,25 | 171,35 | −1 326 592 | 39 519 479 |
2021-11-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −10 365 | 238 378 | −4,17 | 170,36 | −1 765 781 | 40 610 076 |
2021-11-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 33 978 | 248 743 | 15,82 | 7,10 | 241 244 | 1 766 075 |
2021-11-08 |
|
4 | BEAM |
Beam Therapeutics Inc.
Stock Option (Right to Buy) |
A - Award | 13 133 | 13 133 | |||||
2021-08-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −33 979 | 33 978 | −50,00 | |||
2021-08-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −214 | 214 765 | −0,10 | 201,55 | −43 132 | 43 285 886 |
2021-08-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 828 | 214 979 | −1,75 | 200,84 | −768 816 | 43 176 382 |
2021-08-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −23 336 | 218 807 | −9,64 | 199,92 | −4 665 333 | 43 743 895 |
2021-08-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 160 | 242 143 | −1,69 | 198,93 | −827 549 | 48 169 507 |
2021-08-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 441 | 246 303 | −0,98 | 198,02 | −483 367 | 48 772 920 |
2021-08-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 33 979 | 248 744 | 15,82 | 7,10 | 241 251 | 1 766 082 |
2021-06-02 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS, INC.
Restricted stock units |
M - Exercise | −1 686 | 0 | −100,00 | ||||
2021-06-02 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS, INC.
Common stock |
M - Exercise | 1 686 | 28 443 | 6,30 | ||||
2021-06-02 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS, INC.
Common stock |
G - Gift | −3 415 | 26 757 | −11,32 | ||||
2021-05-24 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS, INC.
Stock options (right to buy) |
A - Award | 8 888 | 8 888 | |||||
2021-05-24 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS, INC.
Restricted stock unit |
A - Award | 1 585 | 1 585 | |||||
2021-05-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −33 979 | 67 957 | −33,33 | |||
2021-05-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 023 | 214 765 | −0,47 | 134,37 | −137 461 | 28 857 973 |
2021-05-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 624 | 215 788 | −0,75 | 133,56 | −216 901 | 28 820 645 |
2021-05-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 481 | 217 412 | −1,58 | 132,32 | −460 606 | 28 767 956 |
2021-05-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −11 203 | 220 893 | −4,83 | 131,18 | −1 469 610 | 28 976 744 |
2021-05-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −9 121 | 232 096 | −3,78 | 130,34 | −1 188 831 | 30 251 393 |
2021-05-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 512 | 241 217 | −1,84 | 129,32 | −583 492 | 31 194 182 |
2021-05-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 015 | 245 729 | −1,21 | 128,30 | −386 824 | 31 527 031 |
2021-05-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 33 979 | 248 744 | 15,82 | 7,10 | 241 251 | 1 766 082 |
2021-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −270 | 214 765 | −0,13 | 134,62 | −36 347 | 28 911 578 | |
2021-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −7 237 | 215 035 | −3,26 | 131,75 | −953 475 | 28 330 861 | |
2021-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 16 236 | 222 272 | 7,88 | ||||
2021-02-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −33 979 | 101 936 | −25,00 | |||
2021-02-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −599 | 206 036 | −0,29 | 154,59 | −92 599 | 31 851 105 |
2021-02-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −431 | 206 635 | −0,21 | 153,33 | −66 085 | 31 683 345 |
2021-02-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 138 | 207 066 | −0,55 | 152,46 | −173 499 | 31 569 282 |
2021-02-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 415 | 208 204 | −0,68 | 151,31 | −214 104 | 31 503 347 |
2021-02-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 054 | 209 619 | −0,97 | 150,22 | −308 552 | 31 488 966 |
2021-02-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 364 | 211 673 | −0,64 | 148,96 | −203 181 | 31 530 810 |
2021-02-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 375 | 213 037 | −2,01 | 148,00 | −647 500 | 31 529 476 |
2021-02-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −6 097 | 217 412 | −2,73 | 146,98 | −896 137 | 31 955 216 |
2021-02-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −9 376 | 223 509 | −4,03 | 146,13 | −1 370 115 | 32 661 370 |
2021-02-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −6 129 | 232 885 | −2,56 | 145,15 | −889 624 | 33 803 258 |
2021-02-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 001 | 239 014 | −0,42 | 143,88 | −144 024 | 34 389 334 |
2021-02-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 33 979 | 240 015 | 16,49 | 7,10 | 241 251 | 1 704 106 |
2021-02-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 79 998 | 79 998 | |||||
2021-02-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −307 | 206 036 | −0,15 | 151,94 | −46 645 | 31 304 492 | |
2021-02-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −5 412 | 206 343 | −2,56 | 156,00 | −844 272 | 32 189 508 | |
2021-02-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2017 (right to buy) |
A - Award | 17 504 | 52 500 | 50,02 | ||||
2021-02-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 14 166 | 211 755 | 7,17 | ||||
2020-11-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −34 765 | 0 | −100,00 | |||
2020-11-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −102 | 197 589 | −0,05 | 126,62 | −12 915 | 25 018 719 |
2020-11-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −10 187 | 197 691 | −4,90 | 125,35 | −1 276 940 | 24 780 567 |
2020-11-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −5 489 | 207 878 | −2,57 | 124,49 | −683 326 | 25 878 732 |
2020-11-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −18 987 | 213 367 | −8,17 | 123,55 | −2 345 844 | 26 361 493 |
2020-11-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 34 765 | 232 354 | 17,59 | 9,14 | 317 752 | 2 123 716 |
2020-08-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −34 765 | 34 765 | −50,00 | |||
2020-08-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −8 542 | 197 589 | −4,14 | 136,86 | −1 169 058 | 27 042 031 |
2020-08-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −21 448 | 206 131 | −9,42 | 136,07 | −2 918 429 | 28 048 245 |
2020-08-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 775 | 227 579 | −2,06 | 135,09 | −645 055 | 30 743 647 |
2020-08-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 34 765 | 232 354 | 17,59 | 9,14 | 317 752 | 2 123 716 |
2020-06-01 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS, INC.
Restricted stock units |
M - Exercise | −1 878 | 0 | −100,00 | ||||
2020-06-01 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS, INC.
Common stock |
M - Exercise | 1 878 | 30 172 | 6,64 | ||||
2020-06-01 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS, INC.
Restricted stock units |
A - Award | 1 686 | 1 686 | |||||
2020-06-01 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS, INC.
Stock options (right to buy) |
A - Award | 8 096 | 8 096 | |||||
2020-05-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −34 765 | 69 530 | −33,33 | |||
2020-05-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −5 013 | 197 589 | −2,47 | 144,33 | −723 526 | 28 518 020 |
2020-05-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −16 315 | 202 602 | −7,45 | 143,46 | −2 340 550 | 29 065 283 |
2020-05-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −13 437 | 218 917 | −5,78 | 142,51 | −1 914 907 | 31 197 862 |
2020-05-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 34 765 | 232 354 | 17,59 | 9,14 | 317 752 | 2 123 716 |
2020-04-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −256 | 197 589 | −0,13 | 106,27 | −27 205 | 20 997 783 | |
2020-04-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −6 315 | 197 845 | −3,09 | 104,75 | −661 496 | 20 724 264 | |
2020-04-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 14 167 | 204 160 | 7,46 | ||||
2020-02-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 88 240 | 88 240 | |||||
2020-02-28 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS, INC.
Common stock |
G - Gift | −1 915 | 28 294 | −6,34 | ||||
2020-02-28 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS, INC.
Common stock |
G - Gift | −2 400 | 30 209 | −7,36 | ||||
2020-02-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −34 765 | 104 295 | −25,00 | |||
2020-02-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −502 | 189 993 | −0,26 | 133,42 | −66 977 | 25 348 866 |
2020-02-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −18 065 | 190 495 | −8,66 | 132,81 | −2 399 213 | 25 299 641 |
2020-02-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −6 887 | 208 560 | −3,20 | 131,61 | −906 398 | 27 448 582 |
2020-02-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −5 053 | 215 447 | −2,29 | 131,07 | −662 297 | 28 238 638 |
2020-02-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 586 | 220 500 | −0,71 | 129,33 | −205 117 | 28 517 265 |
2020-02-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 672 | 222 086 | −1,19 | 128,62 | −343 673 | 28 564 701 |
2020-02-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 34 765 | 224 758 | 18,30 | 9,14 | 317 752 | 2 054 288 |
2019-12-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2017 (right to buy) |
A - Award | 17 498 | 34 996 | 100,00 | ||||
2019-11-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2017 (right to buy) |
A - Award | 17 498 | 17 498 | |||||
2019-10-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −49 456 | 0 | −100,00 | |||
2019-10-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 870 | 189 993 | −0,97 | 80,31 | −150 180 | 15 258 338 |
2019-10-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −26 754 | 191 863 | −12,24 | 79,80 | −2 134 969 | 15 310 667 |
2019-10-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −20 832 | 218 617 | −8,70 | 78,92 | −1 644 061 | 17 253 254 |
2019-10-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 49 456 | 239 449 | 26,03 | 16,43 | 812 562 | 3 934 147 |
2019-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy) |
A - Award | 6 250 | 25 000 | 33,33 | ||||
2019-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy) |
A - Award | 16 250 | 65 000 | 33,33 | ||||
2019-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 34 | 3 133 | 1,10 | ||||
2019-06-14 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Common stock |
G - Gift | −5 000 | 32 609 | −13,29 | ||||
2019-06-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy) |
A - Award | 6 250 | 18 750 | 50,00 | ||||
2019-05-31 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Restricted stock units |
M - Exercise | −1 400 | 0 | −100,00 | ||||
2019-05-31 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Common stock |
M - Exercise | 1 400 | 37 609 | 3,87 | ||||
2019-05-31 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Restricted stock units |
A - Award | 1 878 | 1 878 | |||||
2019-05-31 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Stock option (right to buy) |
A - Award | 8 919 | 8 919 | |||||
2019-05-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −49 457 | 49 456 | −50,00 | |||
2019-05-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −49 457 | 189 993 | −20,65 | 70,00 | −3 461 990 | 13 299 510 |
2019-05-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 49 457 | 239 450 | 26,03 | 16,43 | 812 579 | 3 934 164 |
2019-05-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 61 | 3 099 | 2,01 | ||||
2019-03-01 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 85 000 | 85 000 | |||||
2018-11-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −98 636 | 0 | −100,00 | ||||
2018-11-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −59 940 | 189 993 | −23,98 | 72,68 | −4 356 439 | 13 808 691 | |
2018-11-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 98 636 | 249 933 | 65,19 | 21,35 | 2 105 879 | 5 336 070 | |
2018-11-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 17 | 3 038 | 0,56 | ||||
2018-11-06 |
|
4/A | AGIO |
AGIOS PHARMACEUTICALS INC
Common stock |
S - Sale | 0 | 36 209 | 0,00 | ||||
2018-09-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy) |
A - Award | 6 250 | 12 500 | 100,00 | ||||
2018-09-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy) |
A - Award | 16 250 | 48 750 | 50,00 | ||||
2018-09-13 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Common stock |
S - Sale | −14 162 | 22 047 | −39,11 | 71,74 | −1 015 982 | 1 581 652 | |
2018-09-13 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Common stock |
S - Sale | −2 400 | 36 209 | −6,22 | 73,82 | −177 168 | 2 672 948 | |
2018-09-13 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Common stock |
S - Sale | −11 155 | 38 609 | −22,42 | 72,52 | −808 961 | 2 799 925 | |
2018-08-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy) |
A - Award | 16 250 | 32 500 | 100,00 | ||||
2018-08-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Based Stock Option 2013 (right to buy) |
A - Award | 25 000 | 75 000 | 50,00 | ||||
2018-08-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Based Stock Option 2014 (right to buy) |
A - Award | 25 000 | 75 000 | 50,00 | ||||
2018-07-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −50 000 | 98 636 | −33,64 | |||
2018-07-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 400 | 151 297 | −0,92 | 106,25 | −148 750 | 16 075 306 |
2018-07-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −34 995 | 152 697 | −18,64 | 105,83 | −3 703 521 | 16 159 924 |
2018-07-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −7 758 | 187 692 | −3,97 | 104,83 | −813 271 | 19 675 752 |
2018-07-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 847 | 195 450 | −1,93 | 103,69 | −398 895 | 20 266 210 |
2018-07-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 000 | 199 297 | −0,99 | 102,51 | −205 020 | 20 429 935 |
2018-07-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 50 000 | 201 297 | 33,05 | 21,35 | 1 067 500 | 4 297 691 |
2018-07-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 31 | 3 021 | 1,04 | ||||
2018-07-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 30 | 2 990 | 1,01 | ||||
2018-06-04 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Restricted stock units |
A - Award | 1 400 | 1 400 | |||||
2018-06-04 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Stock option (right to buy) |
A - Award | 5 700 | 5 700 | |||||
2018-03-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 52 500 | 52 500 | |||||
2017-12-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Based Stock Option 2016 (right to buy) |
A - Award | 6 250 | 6 250 | |||||
2017-12-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | 1 587 | 148 413 | 1,08 | ||||
2017-12-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 1 587 | 151 297 | 1,06 | 63,00 | 99 981 | 9 531 711 | |
2017-11-24 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −73 415 | 0 | −100,00 | |||
2017-11-24 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 683 | 149 710 | −1,76 | 132,73 | −356 115 | 19 871 008 |
2017-11-24 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −20 433 | 152 393 | −11,82 | 131,82 | −2 693 478 | 20 088 445 |
2017-11-24 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −25 036 | 172 826 | −12,65 | 130,88 | −3 276 712 | 22 619 467 |
2017-11-24 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −25 263 | 197 862 | −11,32 | 129,97 | −3 283 432 | 25 716 124 |
2017-11-24 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 73 415 | 223 125 | 49,04 | 31,39 | 2 304 497 | 7 003 894 |
2017-11-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −74 000 | 73 415 | −50,20 | |||
2017-11-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −600 | 149 710 | −0,40 | 130,22 | −78 131 | 19 494 937 |
2017-11-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 850 | 150 310 | −3,13 | 129,57 | −628 414 | 19 475 667 |
2017-11-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −10 571 | 155 160 | −6,38 | 128,48 | −1 358 204 | 19 935 577 |
2017-11-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −7 120 | 165 731 | −4,12 | 127,54 | −908 085 | 21 137 332 |
2017-11-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −28 399 | 172 851 | −14,11 | 126,60 | −3 595 399 | 21 883 455 |
2017-11-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −22 460 | 201 250 | −10,04 | 125,54 | −2 819 718 | 25 265 730 |
2017-11-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 74 000 | 223 710 | 49,43 | 31,39 | 2 322 860 | 7 022 257 |
2017-11-08 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy) |
A - Award | 16 250 | 16 250 | |||||
2017-09-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2013 (right to buy) |
A - Award | 25 000 | 25 000 | |||||
2017-09-18 |
|
4 | BLUE |
bluebird bio, Inc.
Stock Option (right to buy) |
M - Exercise | 18 868 | 0 | −100,00 | ||||
2017-09-18 |
|
4 | BLUE |
bluebird bio, Inc.
Common Stock |
S - Sale | −600 | 5 843 | −9,31 | 131,82 | −79 090 | 770 205 | |
2017-09-18 |
|
4 | BLUE |
bluebird bio, Inc.
Common Stock |
S - Sale | −18 268 | 6 443 | −73,93 | 131,19 | −2 396 643 | 845 280 | |
2017-09-18 |
|
4 | BLUE |
bluebird bio, Inc.
Common Stock |
M - Exercise | 18 868 | 24 711 | 322,92 | 2,09 | 39 434 | 51 646 | |
2017-08-28 |
|
4 | BLUE |
bluebird bio, Inc.
Stock Option (right to buy) |
M - Exercise | 13 839 | 18 868 | 275,18 | ||||
2017-08-28 |
|
4 | BLUE |
bluebird bio, Inc.
Common Stock |
S - Sale | −6 385 | 8 597 | −42,62 | 96,32 | −615 019 | 828 085 | |
2017-08-28 |
|
4 | BLUE |
bluebird bio, Inc.
Common Stock |
S - Sale | −4 700 | 14 982 | −23,88 | 95,13 | −447 089 | 1 425 167 | |
2017-08-28 |
|
4 | BLUE |
bluebird bio, Inc.
Common Stock |
M - Exercise | 13 839 | 19 682 | 236,85 | 2,09 | 28 924 | 41 135 | |
2017-08-28 |
|
4 | BLUE |
bluebird bio, Inc.
Common Stock |
S - Sale | −2 754 | 5 843 | −32,03 | 96,74 | −266 425 | 565 258 | |
2017-07-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2014 (right to buy) |
A - Award | 25 000 | 50 000 | 100,00 | ||||
2017-06-15 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Stock option (right to buy) |
A - Award | 8 000 | 8 000 | |||||
2017-06-12 |
|
4 | BLUE |
bluebird bio, Inc.
Stock Option (right to buy) |
A - Award | 4 000 | 4 000 | |||||
2017-06-12 |
|
4 | BLUE |
bluebird bio, Inc.
Common Stock |
A - Award | 1 000 | 5 843 | 20,65 | ||||
2017-03-06 |
|
4 | BLUE |
bluebird bio, Inc.
Stock Option (right to buy) |
M - Exercise | −12 917 | 0 | −100,00 | ||||
2017-03-06 |
|
4 | BLUE |
bluebird bio, Inc.
Stock Option (right to buy) |
M - Exercise | −922 | 0 | −100,00 | ||||
2017-03-06 |
|
4 | BLUE |
bluebird bio, Inc.
Common Stock |
S - Sale | −13 839 | 4 843 | −74,08 | 85,02 | −1 176 646 | 411 771 | |
2017-03-06 |
|
4 | BLUE |
bluebird bio, Inc.
Common Stock |
M - Exercise | 12 917 | 18 682 | 224,06 | 5,50 | 71 049 | 102 758 | |
2017-03-06 |
|
4 | BLUE |
bluebird bio, Inc.
Common Stock |
M - Exercise | 922 | 5 765 | 19,04 | 0,95 | 874 | 5 468 | |
2017-01-23 |
|
4 | BLUE |
bluebird bio, Inc.
Common Stock |
G - Gift | −1 450 | 4 843 | −23,04 | ||||
2017-01-06 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −1 340 | 144 641 | −0,92 | ||||
2017-01-06 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 1 340 | 149 710 | 0,90 | 18,66 | 25 004 | 2 793 589 | |
2016-12-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 25 000 | 25 000 | |||||
2016-12-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −30 151 | 0 | −100,00 | ||||
2016-12-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −22 710 | 148 370 | −13,27 | 42,61 | −967 673 | 6 322 046 | |
2016-12-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 30 151 | 171 080 | 21,39 | 22,75 | 685 935 | 3 892 070 | |
2016-10-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −4 019 | 145 981 | −2,68 | ||||
2016-10-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −3 521 | 135 915 | −2,53 | ||||
2016-10-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 4 019 | 140 929 | 2,94 | 18,66 | 74 995 | 2 629 735 | |
2016-10-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 3 521 | 136 910 | 2,64 | 7,10 | 24 999 | 972 061 | |
2016-07-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −15 075 | 30 151 | −33,33 | |||
2016-07-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 418 | 133 389 | −1,78 | 66,00 | −159 586 | 8 803 581 |
2016-07-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −12 057 | 135 807 | −8,15 | 65,56 | −790 430 | 8 903 208 |
2016-07-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −600 | 147 864 | −0,40 | 64,29 | −38 575 | 9 506 428 |
2016-07-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 15 075 | 148 464 | 11,30 | 22,75 | 342 956 | 3 377 556 |
2016-07-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −15 076 | 45 226 | −25,00 | |||
2016-07-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 505 | 133 389 | −1,12 | 64,56 | −97 159 | 8 611 274 |
2016-07-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −13 571 | 134 894 | −9,14 | 63,73 | −864 839 | 8 596 390 |
2016-07-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 15 076 | 148 465 | 11,30 | 22,75 | 342 979 | 3 377 579 |
2016-06-23 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Stock option (right to buy) |
A - Award | 8 000 | 41 125 | 24,15 | ||||
2016-06-03 |
|
4 | BLUE |
bluebird bio, Inc.
Stock Option (right to buy) |
A - Award | 4 000 | 4 000 | |||||
2016-06-03 |
|
4 | BLUE |
bluebird bio, Inc.
Common Stock |
A - Award | 1 000 | 1 000 | |||||
2016-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | 15 075 | 60 302 | 33,33 | |||
2016-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 405 | 133 389 | −1,77 | 68,24 | −164 128 | 9 103 052 |
2016-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −12 670 | 135 794 | −8,53 | 67,38 | −853 645 | 9 149 161 |
2016-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 15 075 | 148 464 | 11,30 | 22,75 | 342 956 | 3 377 556 |
2016-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | 15 076 | 75 377 | 25,00 | |||
2016-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −300 | 133 389 | −0,22 | 68,71 | −20 612 | 9 164 718 |
2016-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −5 405 | 133 689 | −3,89 | 68,00 | −367 555 | 9 091 226 |
2016-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −9 371 | 139 094 | −6,31 | 67,02 | −628 032 | 9 321 899 |
2016-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 15 076 | 148 465 | 11,30 | 22,75 | 342 979 | 3 377 579 |
2016-02-03 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2014 (right to buy) |
A - Award | 25 000 | 25 000 | |||||
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −15 076 | 90 453 | −14,29 | |||
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −325 | 133 389 | −0,24 | 74,61 | −24 249 | 9 952 567 |
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 865 | 133 714 | −1,38 | 73,77 | −137 577 | 9 863 774 |
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −400 | 135 579 | −0,29 | 72,51 | −29 005 | 9 831 172 |
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 136 | 135 979 | −0,83 | 71,79 | −81 548 | 9 761 307 |
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −930 | 137 115 | −0,67 | 70,43 | −65 498 | 9 656 776 |
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 114 | 138 045 | −1,51 | 69,40 | −146 704 | 9 579 798 |
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 406 | 140 159 | −3,05 | 68,35 | −301 155 | 9 580 008 |
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 700 | 144 565 | −1,83 | 67,39 | −181 961 | 9 742 669 |
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 200 | 147 265 | −0,81 | 66,28 | −79 537 | 9 760 842 |
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 15 076 | 148 465 | 11,30 | 22,75 | 342 979 | 3 377 579 |
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −15 076 | 105 529 | −12,50 | |||
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −200 | 133 389 | −0,15 | 78,04 | −15 608 | 10 409 678 |
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −200 | 133 589 | −0,15 | 76,95 | −15 390 | 10 279 674 |
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 245 | 133 789 | −1,65 | 75,97 | −170 550 | 10 163 803 |
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 400 | 136 034 | −2,44 | 75,01 | −255 050 | 10 204 550 |
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −5 112 | 139 434 | −3,54 | 74,14 | −378 993 | 10 337 344 |
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 281 | 144 546 | −0,88 | 73,03 | −93 546 | 10 555 587 |
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −800 | 145 827 | −0,55 | 71,81 | −57 447 | 10 471 662 |
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 838 | 146 627 | −1,24 | 70,95 | −130 401 | 10 402 760 |
2016-01-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 15 076 | 148 465 | 11,30 | 22,75 | 342 979 | 3 377 579 |
2015-12-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 65 000 | 65 000 | |||||
2015-12-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −58 689 | 0 | −100,00 | |||
2015-12-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −700 | 133 389 | −0,52 | 106,60 | −74 622 | 14 219 601 |
2015-12-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −16 984 | 134 089 | −11,24 | 106,02 | −1 800 596 | 14 215 740 |
2015-12-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −20 238 | 151 073 | −11,81 | 105,16 | −2 128 192 | 15 886 565 |
2015-12-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −10 784 | 171 311 | −5,92 | 104,00 | −1 121 541 | 17 816 430 |
2015-12-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −9 983 | 182 095 | −5,20 | 103,15 | −1 029 764 | 18 783 427 |
2015-12-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 58 689 | 192 078 | 44,00 | 13,12 | 770 000 | 2 520 063 |
2015-11-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −10 564 | 139 436 | −7,04 | ||||
2015-11-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −58 690 | 58 689 | −50,00 | |||
2015-11-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −8 070 | 133 389 | −5,70 | 103,97 | −839 023 | 13 868 201 |
2015-11-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −23 483 | 141 459 | −14,24 | 103,13 | −2 421 832 | 14 588 851 |
2015-11-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −27 137 | 164 942 | −14,13 | 102,34 | −2 777 078 | 16 879 422 |
2015-11-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 10 564 | 192 079 | 5,82 | 7,10 | 75 004 | 1 363 761 | |
2015-11-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 58 690 | 181 515 | 47,78 | 13,12 | 770 013 | 2 381 477 |
2015-06-25 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Stock option (right to buy) |
A - Award | 10 625 | 33 125 | 47,22 | ||||
2015-06-17 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Common stock |
G - Gift | −410 | 49 764 | −0,82 | ||||
2015-06-08 |
|
4 | BLUE |
bluebird bio, Inc.
Stock Option (right to buy) |
A - Award | 7 500 | 7 500 | |||||
2015-05-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
A - Award | 75 000 | 75 000 | |||||
2015-04-30 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Common stock |
G - Gift | −515 | 50 174 | −1,02 | ||||
2015-01-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 10 000 | 122 825 | 8,86 | 95,00 | 950 000 | 11 668 375 | |
2014-12-22 |
|
4 | BLUE |
bluebird bio, Inc.
Common Stock |
P - Purchase | 2 352 | 5 293 | 79,97 | 85,00 | 199 920 | 449 905 | |
2014-12-18 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Common stock |
P - Purchase | 1 806 | 50 689 | 3,69 | 110,75 | 200 014 | 5 613 807 | |
2014-12-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −8 205 | 139 060 | −5,57 | ||||
2014-12-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 8 205 | 112 825 | 7,84 | 9,14 | 74 994 | 1 031 220 | |
2014-12-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance-Based Stock Option (Right to Buy) |
A - Award | 25 000 | 25 000 | |||||
2014-09-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −56 834 | 0 | −100,00 | |||
2014-09-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −37 872 | 104 620 | −26,58 | 79,23 | −3 000 549 | 8 288 907 |
2014-09-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −18 962 | 142 492 | −11,74 | 78,12 | −1 481 274 | 11 131 190 |
2014-09-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 56 834 | 161 454 | 54,32 | 7,47 | 424 550 | 1 206 061 |
2014-09-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −56 834 | 56 834 | −50,00 | |||
2014-09-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −400 | 104 620 | −0,38 | 78,10 | −31 242 | 8 171 282 |
2014-09-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −15 849 | 105 020 | −13,11 | 77,71 | −1 231 696 | 8 161 566 |
2014-09-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −23 286 | 120 869 | −16,15 | 76,54 | −1 782 317 | 9 251 350 |
2014-09-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −13 899 | 144 155 | −8,79 | 75,65 | −1 051 393 | 10 904 634 |
2014-09-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 400 | 158 054 | −2,11 | 74,74 | −254 102 | 11 812 324 |
2014-09-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 56 834 | 161 454 | 54,32 | 7,47 | 424 550 | 1 206 061 |
2014-09-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
G - Gift | −1 700 | 104 620 | −1,60 | ||||
2014-07-14 |
|
4 | BLUE |
bluebird bio, Inc.
Common Stock |
P - Purchase | 2 941 | 2 941 | 34,00 | 99 994 | 99 994 | ||
2014-06-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −56 834 | 113 668 | −33,33 | |||
2014-06-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 800 | 106 320 | −1,66 | 66,61 | −119 901 | 7 082 156 |
2014-06-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −5 570 | 108 120 | −4,90 | 65,50 | −364 811 | 7 081 395 |
2014-06-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −49 464 | 113 690 | −30,32 | 64,66 | −3 198 214 | 7 350 900 |
2014-06-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 56 834 | 163 154 | 53,46 | 7,47 | 424 550 | 1 218 760 |
2014-06-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −56 834 | 170 502 | −25,00 | |||
2014-06-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −32 846 | 106 320 | −23,60 | 66,29 | −2 177 266 | 7 047 644 |
2014-06-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −23 988 | 139 166 | −14,70 | 65,86 | −1 579 905 | 9 165 793 |
2014-06-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 56 834 | 163 154 | 53,46 | 7,47 | 424 550 | 1 218 760 |
2014-06-24 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Common stock |
P - Purchase | 2 300 | 48 883 | 4,94 | 43,98 | 101 154 | 2 149 874 | |
2014-06-12 |
|
4 | BLUE |
bluebird bio, Inc.
Stock Option (right to buy) |
A - Award | 7 500 | 7 500 | |||||
2014-06-05 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Stock Option (right to buy) |
A - Award | 12 500 | 22 500 | 125,00 | ||||
2014-05-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | 22 664 | 227 336 | 11,07 | |||
2014-05-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | 34 170 | 0 | −100,00 | |||
2014-05-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 926 | 106 320 | −2,68 | 56,71 | −165 940 | 6 029 630 |
2014-05-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −53 908 | 109 246 | −33,04 | 56,06 | −3 022 287 | 6 124 746 |
2014-05-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 22 664 | 163 154 | 16,13 | 7,47 | 169 300 | 1 218 760 |
2014-05-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 34 170 | 140 490 | 32,14 | 6,78 | 231 673 | 952 522 |
2014-05-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | 56 834 | 34 170 | −250,77 | |||
2014-05-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −19 500 | 106 320 | −15,50 | 57,64 | −1 124 076 | 6 128 806 |
2014-05-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −37 334 | 125 820 | −22,88 | 57,20 | −2 135 639 | 7 197 357 |
2014-05-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 56 834 | 163 154 | 53,46 | 6,78 | 385 335 | 1 106 184 |
2014-04-30 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Common stock |
P - Purchase | 2 250 | 46 583 | 5,08 | 44,00 | 99 000 | 2 049 652 | |
2014-04-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −3 185 | 147 415 | −2,11 | ||||
2014-04-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −4 684 | 148 636 | −3,06 | ||||
2014-04-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −6 087 | 98 913 | −5,80 | ||||
2014-04-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −2 735 | 147 265 | −1,82 | ||||
2014-04-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −4 395 | 120 605 | −3,52 | ||||
2014-04-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −7 621 | 117 379 | −6,10 | ||||
2014-04-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 6 087 | 106 320 | 6,07 | 16,43 | 100 009 | 1 746 838 | |
2014-04-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 4 684 | 100 233 | 4,90 | 21,35 | 100 003 | 2 139 975 | |
2014-04-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 3 185 | 95 549 | 3,45 | 31,39 | 99 977 | 2 999 283 | |
2014-04-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 4 395 | 92 364 | 5,00 | 22,75 | 99 986 | 2 101 281 | |
2014-04-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 7 621 | 87 969 | 9,48 | 13,12 | 99 988 | 1 154 153 | |
2014-04-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 2 735 | 80 348 | 3,52 | 9,14 | 24 998 | 734 381 | |
2014-04-03 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Common stock |
P - Purchase | 8 333 | 44 333 | 23,15 | 18,00 | 149 994 | 797 994 | |
2014-02-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −46 331 | 91 004 | −33,74 | ||||
2014-02-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 46 331 | 77 613 | 148,11 | 6,78 | 314 124 | 526 216 | |
2013-12-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 150 000 | 150 000 | |||||
2013-12-06 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 10 000 | 10 000 | |||||
2013-10-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −12 665 | 46 331 | −21,47 | ||||
2013-10-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 12 665 | 31 282 | 68,03 | 6,78 | 85 869 | 212 092 | |
2013-09-24 |
|
4/A | ALKS |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 10 000 | 10 000 | |||||
2013-09-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −45 263 | 0 | −100,00 | |||
2013-09-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −13 684 | 0 | −100,00 | |||
2013-09-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 100 | 18 617 | −5,58 | 57,02 | −62 726 | 1 061 608 |
2013-09-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 800 | 19 717 | −16,16 | 56,33 | −214 070 | 1 110 741 |
2013-09-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −54 047 | 23 517 | −69,68 | 55,41 | −2 994 728 | 1 303 070 |
2013-09-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 45 263 | 77 564 | 140,13 | 0,95 | 43 000 | 73 686 |
2013-09-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 13 684 | 32 301 | 73,50 | 0,95 | 13 000 | 30 686 |
2013-08-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −60 000 | 45 263 | −57,00 | |||
2013-08-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −40 237 | 18 617 | −68,37 | 49,06 | −1 974 188 | 913 424 |
2013-08-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −19 763 | 58 854 | −25,14 | 48,77 | −963 938 | 2 870 598 |
2013-08-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 60 000 | 78 617 | 322,29 | 0,95 | 57 000 | 74 686 |
2013-07-23 | 3 | AGIO |
AGIOS PHARMACEUTICALS INC
Common Stock |
36 000 | ||||||||
2013-07-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −60 000 | 13 684 | −81,43 | |||
2013-07-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −60 000 | 18 617 | −76,32 | 37,11 | −2 226 822 | 690 946 |
2013-07-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 60 000 | 78 617 | 322,29 | 0,95 | 57 000 | 74 686 |
2013-02-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −28 503 | 18 617 | −60,49 | 23,50 | −669 900 | 437 552 |
2013-02-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −30 000 | 47 120 | −38,90 | 23,47 | −704 019 | 1 105 779 |
2012-12-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 150 000 | 150 000 | |||||
2012-12-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −4 515 | 0 | −100,00 | ||||
2012-12-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −14 102 | 0 | −100,00 | ||||
2012-12-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 14 102 | 77 120 | 22,38 | 0,48 | 6 698 | 36 632 | |
2012-12-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 4 515 | 63 018 | 7,72 | 0,48 | 2 145 | 29 934 | |
2012-10-11 |
|
4 | RGLS |
Regulus Therapeutics Inc.
Series A Preferred Stock |
C - Conversion | −6 150 500 | 0 | −100,00 | ||||
2012-10-11 |
|
4 | RGLS |
Regulus Therapeutics Inc.
Common Stock |
C - Conversion | 6 150 500 | 6 150 500 | |||||
2012-02-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 5 581 | 58 503 | 10,55 | 10,75 | 59 996 | 628 907 | |
2011-10-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | X | 1 480 | 48 980 | 3,12 | 6,75 | 9 989 | 330 581 |
2011-10-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
G - Gift | −2 500 | 47 500 | −5,00 |